Oppenheimer Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS) had its price target lowered by equities research analysts at Oppenheimer from $63.00 to $23.00 in a research report issued on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target points to a potential upside of 111.79% from the company’s previous close.

Other research analysts have also issued research reports about the stock. Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating for the company. HC Wainwright lowered their target price on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Guggenheim lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, December 16th. Scotiabank decreased their price target on Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating for the company in a report on Friday, December 13th. Finally, Wells Fargo & Company boosted their price objective on Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Keros Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $52.56.

Keros Therapeutics Stock Up 3.2 %

Shares of NASDAQ:KROS opened at $10.86 on Thursday. The firm has a market cap of $439.91 million, a P/E ratio of -2.08 and a beta of 1.43. Keros Therapeutics has a 12-month low of $9.77 and a 12-month high of $73.00. The business has a fifty day simple moving average of $37.51 and a 200 day simple moving average of $47.36.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company’s revenue for the quarter was up 4750.0% on a year-over-year basis. During the same period last year, the firm posted ($1.33) earnings per share. As a group, equities research analysts expect that Keros Therapeutics will post -4.74 EPS for the current year.

Institutional Trading of Keros Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. KBC Group NV boosted its holdings in Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the period. Values First Advisors Inc. bought a new position in shares of Keros Therapeutics in the 3rd quarter worth $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Keros Therapeutics in the 2nd quarter valued at $128,000. Finally, LMR Partners LLP acquired a new stake in Keros Therapeutics in the 3rd quarter valued at $213,000. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.